CPA
PGNX

Cowen Prime Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cowen Prime Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$3K – 256
2015
Q4 		$3K Sell
500
-37,500
-99% -$246K ﹤0.01% 204
2015
Q3 		$217K Hold
38,000
– – 0.1% 97
2015
Q2 		$283K Buy
+38,000
New +$230K 0.11% 87

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cowen Prime Advisors's PGNX Position: Q1 2016 in Review

Cowen Prime Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2016, closing a stake of 500 shares — an estimated $3K sold.

Cowen Prime Advisors first reported a position in PGNX in Q2 2015 and held it in 3 quarters. The position peaked at $283K in Q2 2015. 120 funds tracked by Wall St. Rank hold PGNX as of Q1 2016.

  • Cowen Prime Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Cowen Prime Advisors sold 500 Progenics Pharmaceuticals Inc shares in Q1 2016, an estimated $3K.
  • Cowen Prime Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 3 quarters.
  • Cowen Prime Advisors's Progenics Pharmaceuticals Inc position peaked at $283K in Q2 2015.
  • 120 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2016.

Based on Cowen Prime Advisors's 13F filing for Q1 2016, filed 9 May 2016.